OncoMatch/Clinical Trials/NCT04765098
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
Is NCT04765098 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Tamoxifen and Etoposide for glioblastoma multiforme.
Treatment: Tamoxifen · Etoposide — The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Endocrine / hormonal
Cancer type
Glioblastoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: chemoradiotherapy with temozolomide (temozolomide) — first line
progression after previous first line chemoradiotherapy with temozolomide
Cannot have received: radiotherapy
Exception: allowed if not received within the three months before the diagnosis of progression
Not received radiotherapy within the three months before the diagnosis of progression
Lab requirements
Blood counts
anc ≥ 1.5 x 10^9/l; platelets ≥ 100 x 10^9/l
Kidney function
serum creatinine ≤ 1.5 times uln
Liver function
total serum bilirubin ≤ 1.5 times uln; alt < 3 times uln; ast < 3 times uln; alkaline phosphatase < 3 times uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04765098 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages